PharmaBlock Sciences Nanjing Inc
SZSE:300725

Watchlist Manager
PharmaBlock Sciences Nanjing Inc Logo
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Watchlist
Price: 35.76 CNY 1.02% Market Closed
Market Cap: 7.1B CNY
Have any thoughts about
PharmaBlock Sciences Nanjing Inc?
Write Note

PharmaBlock Sciences Nanjing Inc
Investor Relations

PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.

Show more

Earnings Calls

No Earnings Calls Available

Management

Dr. Minmin Yang Ph.D.
Co-Founder, Chairman & CEO
No Bio Available
Ms. Wu Yifei
Secretary, CFO & Accounting Supervisor
No Bio Available
Dr. Shijie Zhang Ph.D.
Chief Technology Officer
No Bio Available
Dr. Jing Li Ph.D.
Sr. VP of Process Chemistry & President of PharmaBlock (USA), Inc.
No Bio Available
Dr. Shuhai Zhao Ph.D.
Co-founder & Chief Scientific Officer
No Bio Available
Dr. David Chen Ph.D.
Executive VP, Chief Operation Officer & Head of CDMO
No Bio Available
Dr. Dezhi Sha Ph.D.
Sr. VP of Process Technology & Manufacturing
No Bio Available

Contacts

Address
JIANGSU
Nanjing
No. 10 Xuefu Road, Hi-tech Industrial Development Zone
Contacts
+862586918230
www.pharmablock.com